<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82265">
  <stage>Registered</stage>
  <submitdate>5/09/2007</submitdate>
  <approvaldate>21/09/2007</approvaldate>
  <actrnumber>ACTRN12607000482460</actrnumber>
  <trial_identification>
    <studytitle>The effect of bronchodilators on lung ventilation in chronic obstructive pulmonary disease</studytitle>
    <scientifictitle>The effect of tiotropium bromide on ventilation perfusion heterogeneity in chronic obstructive pulmonary disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Washout period is one week between interventions.
Single dose of 18µg tiotropium bromide and 200µg salbutamol.  Both drugs are inhaled</interventions>
    <comparator>Placebo is 5.5mg lactose for Spiriva and propellant for Salbutamol</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Outcome 1: Ventilation perfusion before and after treatment</outcome>
      <timepoint>Timepoint: One hour after drug administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Outcome 1: Ventilation heterogeneity measured using multiple breath nitrogen washout technique</outcome>
      <timepoint>Timepoint: One hour after drug administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must have a doctor diagnosis of COPD, greater than 15pack year smoking history and obstructed lung function that cannot be normalised with bronchodilator.  Subjects must all be over the age of 50 with no history of asthma or allergic disease.
Minimum age: 50 years for females and 40 years for males</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Females under the age of 50years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects are enrolled from our volunteer database and respiratory clinic.  Allocation sequence kept by an independent researcher in a password protected file</concealment>
    <sequence>Random number generator in Microsoft excel used to determine treatment sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>The Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>Royal Prince Alfred Hospital
Level 3 Building 92
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Boehringer Ingelheim</fundingname>
      <fundingaddress>Corporate Headquarters
Binger Str. 173
55216 Ingelheim</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>CRC for asthma and airways</fundingname>
      <fundingaddress>Medical Foundation Building
Level 3
92 Parramatta Road Camperdown</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chronic Obstructive Pulmonary Disease (COPD) is a common disorder which causes changes within the airways and blood vessels of the lung.  As a result of these changes, it can cause problems with breathing and the way air and oxygen travels to different parts of the lung.  We have several different ways of looking at how bad COPD is, however none of these are perfect.  By understanding better the way in which airways behave in COPD, and the effects this has on blood flow within the lung, the better able we will be to investigate, develop new medications, and treat COPD.  In this study we will be investigating the way COPD affects breathing and blood flow by looking at changes in lung function.  We will then compare this information with pictures of breathing and blood flow obtained from a nuclear medicine scan.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney central coast human research ethics committee</ethicname>
      <ethicaddress>Research office
Level 4, Vindin house
Royal North Shore Hospital
Pacific Highway St Leonards NSW</ethicaddress>
      <ethicapprovaldate>13/04/2007</ethicapprovaldate>
      <hrec>0512-232M(SP)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chantale Diba</name>
      <address>PO Box M77 Missenden Rd
Camperdown NSW 2050</address>
      <phone>61 2 9515 6175</phone>
      <fax>61 2 9550 6115</fax>
      <email>chantale@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Newton-John</name>
      <address>PO Box M77 Missenden Rd
Camperdown NSW 2050</address>
      <phone>61 2 9515 6578</phone>
      <fax>61 2 9550 5865</fax>
      <email>sarahnj@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>